 HUTCHMED China Limited NASDAQ: HCM and AstraZeneca Plc NASDAQ: AZN have initiated a Phase 2 study of Orpathys savolitinib in patients with advanced or metastatic MET amplified gastric cancer GC or adenocarcinoma of the gastroesophageal junction GEJ. Orpathys is an oral, potent, and highly selective small-molecule inhibitor of MET, a receptor tyrosine kinase. 